ArticleProstate cancer and prostatic diseases2023

Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.

Mike Wenzel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.